FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087568644> ?p ?o ?g. }

• W2087568644 endingPage "303" @default.
• W2087568644 startingPage "297" @default.
• W2087568644 abstract "Nongastrointestinal-type mucinous borderline tumors have been described as displaying endocervical and serous differentiation and hence have been termed endocervical-type mucinous borderline tumors, mixed-epithelial papillary cystadenoma of borderline malignancy of mullerian type, or atypical proliferative seromucinous tumors. A striking feature of these tumors is their frequent association with endometriosis, which has been reported in a third to a half of cases. This is an unusual finding, as pure endocervical and serous tumors are not usually associated with endometriosis. ARID1A is a recently identified tumor suppressor, which frequently loses its expression and is mutated in endometrium-related carcinomas including ovarian clear cell, ovarian endometrioid, and uterine endometrioid carcinomas. Although ARID1A mutations and their expression have been studied in gynecologic cancer, the expression pattern of ARID1A has not been investigated in ovarian atypical proliferative (borderline) tumors. In this study, we analyzed ARID1A expression in serous, gastrointestinal-type and endocervical-type (seromucinous) mucinous, and endometrioid atypical proliferative (borderline) tumors using immunohistochemistry and performed mutational analysis in selected cases. We observed loss of ARID1A staining in 8 (33%) of 24 seromucinous tumors. In contrast, ARID1A staining was retained in all the other 32 tumors except in 1 endometrioid tumor (P<0.01). Mutational analysis was performed on 2 representative seromucinous tumors, which showed complete loss of ARID1A. Both tumors harbored somatic inactivating ARID1A mutations. Previous studies have reported loss of expression and/or mutation of ARID1A in 30% to 57% of endometrioid and clear cell carcinomas but only rarely in serous tumors. In summary, these tumors often contain endocervical-type mucinous epithelium, but they typically display papillary architecture, unlike most endocervical neoplasms, and their immunophenotype is different from both endocervical and serous tumors. Moreover, they frequently contain ciliated cells, endometrial-type cells, cells with abundant eosinophilic cytoplasm, and hobnail-shaped cells, all of which can be found in endometrioid tumors. The loss of expression of ARID1A and the presence of inactivating mutations of the ARID1A gene further link this tumor to endometrioid and clear cell tumors, as does the frequent association with endometriosis. Accordingly, we suggest designating these tumors atypical proliferative (borderline) papillary müllerian tumors as this designation more accurately reflects their clinicopathologic, immunohistochemical, and molecular genetic features." @default.
• W2087568644 created "2016-06-24" @default.
• W2087568644 creator A5004454109 @default.
• W2087568644 creator A5014887786 @default.
• W2087568644 creator A5019250137 @default.
• W2087568644 creator A5033744514 @default.
• W2087568644 creator A5041625714 @default.
• W2087568644 creator A5045591857 @default.
• W2087568644 creator A5067344028 @default.
• W2087568644 date "2012-07-01" @default.
• W2087568644 modified "2023-09-28" @default.
• W2087568644 title "Endocervical-type Mucinous Borderline Tumors are Related to Endometrioid Tumors Based on Mutation and Loss of Expression of ARID1A" @default.
• W2087568644 cites W1863364305 @default.
• W2087568644 cites W1975141727 @default.
• W2087568644 cites W1978869914 @default.
• W2087568644 cites W1982331680 @default.
• W2087568644 cites W1984249881 @default.
• W2087568644 cites W1988866904 @default.
• W2087568644 cites W1991055728 @default.
• W2087568644 cites W2012136454 @default.
• W2087568644 cites W2017166332 @default.
• W2087568644 cites W2019110880 @default.
• W2087568644 cites W2022385796 @default.
• W2087568644 cites W2024070545 @default.
• W2087568644 cites W2027599519 @default.
• W2087568644 cites W2028539104 @default.
• W2087568644 cites W2031692395 @default.
• W2087568644 cites W2034852369 @default.
• W2087568644 cites W2039189450 @default.
• W2087568644 cites W2040730809 @default.
• W2087568644 cites W2067405757 @default.
• W2087568644 cites W2075053675 @default.
• W2087568644 cites W2091495172 @default.
• W2087568644 cites W2096489607 @default.
• W2087568644 cites W2107350929 @default.
• W2087568644 cites W2115494288 @default.
• W2087568644 cites W2121309328 @default.
• W2087568644 cites W2141683496 @default.
• W2087568644 cites W2156948371 @default.
• W2087568644 cites W2164326598 @default.
• W2087568644 cites W2165119870 @default.
• W2087568644 doi "https://doi.org/10.1097/pgp.0b013e31823f8482" @default.
• W2087568644 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3501990" @default.
• W2087568644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22653341" @default.
• W2087568644 hasPublicationYear "2012" @default.
• W2087568644 type Work @default.
• W2087568644 sameAs 2087568644 @default.
• W2087568644 citedByCount "71" @default.
• W2087568644 countsByYear W20875686442013 @default.
• W2087568644 countsByYear W20875686442014 @default.
• W2087568644 countsByYear W20875686442015 @default.
• W2087568644 countsByYear W20875686442016 @default.
• W2087568644 countsByYear W20875686442017 @default.
• W2087568644 countsByYear W20875686442018 @default.
• W2087568644 countsByYear W20875686442019 @default.
• W2087568644 countsByYear W20875686442020 @default.
• W2087568644 countsByYear W20875686442021 @default.
• W2087568644 countsByYear W20875686442022 @default.
• W2087568644 countsByYear W20875686442023 @default.
• W2087568644 crossrefType "journal-article" @default.
• W2087568644 hasAuthorship W2087568644A5004454109 @default.
• W2087568644 hasAuthorship W2087568644A5014887786 @default.
• W2087568644 hasAuthorship W2087568644A5019250137 @default.
• W2087568644 hasAuthorship W2087568644A5033744514 @default.
• W2087568644 hasAuthorship W2087568644A5041625714 @default.
• W2087568644 hasAuthorship W2087568644A5045591857 @default.
• W2087568644 hasAuthorship W2087568644A5067344028 @default.
• W2087568644 hasBestOaLocation W20875686442 @default.
• W2087568644 hasConcept C104317684 @default.
• W2087568644 hasConcept C121608353 @default.
• W2087568644 hasConcept C126322002 @default.
• W2087568644 hasConcept C142724271 @default.
• W2087568644 hasConcept C150173356 @default.
• W2087568644 hasConcept C204232928 @default.
• W2087568644 hasConcept C2777088508 @default.
• W2087568644 hasConcept C2777546739 @default.
• W2087568644 hasConcept C2778560582 @default.
• W2087568644 hasConcept C2779399171 @default.
• W2087568644 hasConcept C2781199814 @default.
• W2087568644 hasConcept C2781273526 @default.
• W2087568644 hasConcept C501734568 @default.
• W2087568644 hasConcept C502942594 @default.
• W2087568644 hasConcept C55493867 @default.
• W2087568644 hasConcept C71924100 @default.
• W2087568644 hasConcept C86803240 @default.
• W2087568644 hasConceptScore W2087568644C104317684 @default.
• W2087568644 hasConceptScore W2087568644C121608353 @default.
• W2087568644 hasConceptScore W2087568644C126322002 @default.
• W2087568644 hasConceptScore W2087568644C142724271 @default.
• W2087568644 hasConceptScore W2087568644C150173356 @default.
• W2087568644 hasConceptScore W2087568644C204232928 @default.
• W2087568644 hasConceptScore W2087568644C2777088508 @default.
• W2087568644 hasConceptScore W2087568644C2777546739 @default.
• W2087568644 hasConceptScore W2087568644C2778560582 @default.
• W2087568644 hasConceptScore W2087568644C2779399171 @default.
• W2087568644 hasConceptScore W2087568644C2781199814 @default.
• W2087568644 hasConceptScore W2087568644C2781273526 @default.
• W2087568644 hasConceptScore W2087568644C501734568 @default.

• next